حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Dr. Reddy’s Laboratories Ltd ADR
RDYDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Address: 8-2-337, Road No. 3, Hyderabad, India, 500034
Analytics
سعر الهدف في وول ستريت
16.7 USDنسبة السعر إلى الأرباح
19.1013العائد الربحي
1.27 %السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية RDY
تحليلات الأرباح RDY
نمو الأرباح على مدى 5 سنوات
232 %النمو المستمر
4 سنينمعدل الدفع 5 سنوات في المتوسط
29 %تاريخ الأرباح RDY
تقييم الأسهم RDY
المالية RDY
نتائج | 2019 | ديناميات |